Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Morphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 8/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 11/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 7/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ARRB1 | P49407 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine SCHEMBL15501048 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13076870 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL2997 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL5183254 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13696339 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL8049464 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL24599520 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13154676 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL7987114 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL10820235 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137189-B1 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT LLC (US) | 2015-05-06 | — | — | EP | claimed |
| EP-1562953-B1 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT INC (US) | 2009-09-30 | — | — | EP | claimed |
| US-7285665-B2 | Process for the preparation of quaternary N-alkyl morphinan alkaloid salts | MALLINCKRODT INC. (US) | 2007-10-23 | — | — | US | claimed |
| US-20060014771-A1 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts | SpecGx LLC | 2006-01-19 | — | — | US | claimed |
| EP-1562953-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | Mallinckrodt Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| WO-2004043964-A2 | PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS | MALLINCKRODT INC. (US) | 2004-05-27 | — | — | WO | claimed |
| US-11571390-B2 | Abuse deterrent compositions and methods of use | Othemo Life Sciences, Inc. (US) | 2023-02-07 | — | — | US | disclosed |
| US-10857204-B2 | Method for administering omega-conopeptide | TERSERA THERAPEUTICS LLC (US) | 2020-12-08 | — | — | US | disclosed |
| CN-107028968-B | A pharmaceutical composition containing morphine glucuronide or its pharmaceutically acceptable salt | 江苏恒瑞医药股份有限公司 | 2020-12-04 | — | — | CN | disclosed |
| US-10729685-B2 | Orally administrable compositions and methods of deterring abuse by intranasal administration | OHEMO LIFE SCIENCES INC. (US) | 2020-08-04 | — | — | US | disclosed |
| EP-3666255-A1 | MEDICAL DEVICES AND METHODS INCLUDING POLYMERS HAVING BIOLOGICALLY ACTIVE AGENTS THEREIN | MEDTRONIC, INC. (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10653619-B2 | Drug depots for treatment of pain and inflammation | MEDTRONIC, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-10420726-B2 | Abuse deterrent compositions and methods of use | INSPIRION DELIVERY SCIENCES, LLC (US) | 2019-09-24 | — | — | US | disclosed |
| WO-1993002669-A1 | TRANSDERMAL THERAPEUTIC SYSTEMS | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1993-02-18 | — | — | WO | disclosed |
| US-4990617-A | Analgesics, narcotic antagonists | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-02-05 | — | — | US | disclosed |
| US-4814173-A | CATALYST NOT POISIONED BY DRUG | WARNER-LAMBERT COMPANY (US) | 1989-03-21 | — | — | US | disclosed |
| US-4722928-A | N-OXIDES OF NALBUPHINE, NALTREXONE AND NALOXONE; ANALGESICS, APPETITE DEPRESSANTS, NARCOTIC ANTAGONIST | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-02-02 | — | — | US | disclosed |
| EP-0250796-A2 | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1988-01-07 | — | — | EP | disclosed |
| US-4673679-A | ESTERS, CARBONATES, CARBAMATES, OR SULFONATES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-06-16 | — | — | US | disclosed |
| US-4668685-A | Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014771-A1 | Process for the preparation of quaternary n-alkyl morphinan alkaloid salts | TTN, PML, EMD | OPRM1 45/4885OPRD1 164/4885OPRK1 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.